


# 글로벌 제약사 파이프라인 분석

## - Amgen -

2022. 11.

국가신약개발사업단


• 질환별 파이프라인



**AMGEN**

질환분야	개수	비중
Oncology	23	45%
Immunology	12	23%
Musculoskeletal	4	8%
Cardiovascular	3	6%
Metabolic	3	6%
Respiratory	2	4%
Hematology	2	4%
Endocrine	1	2%
Neuroscience	1	5%
<b>합계</b>	<b>51개</b>	<b>100%</b>

- 물질별 파이프라인



**AMGEN**

물질	개수	비중
Antibody	27	53%
Small molecules	14	27%
Protein	4	8%
RNA	2	4%
ADC	2	4%
Cell Therapy	1	2%
Peptide	1	2%
<b>합계</b>	<b>45개</b>	<b>100%</b>

## • 상세 파이프라인

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	Mono/병용	파트너
1	Cardiovascular	Phase 3	CC-10004	Otezla	apremilast	Behcet's disease	Small molecules	Phosphodiesterase-4(PDE-4)	PDE-4 inhibitor	Mono	-
2	Cardiovascular	Phase 3	AMG 145	Repatha	evolocumab	Hypercholesterolemia	Antibody	PCSK9	PSCK9 inhibitor	Mono	-
3	Cardiovascular	Phase 2	AMG890		olpasiran	Cardiovascular disease	RNA	Lipoprotein	Gene silencing	Mono	-
4	Endocrine	Phase 3	AMG 416	Parsabiv	etelcalcetide	Hyperparathyroidism, secondary, pediatric	Peptide	Calcium sensing receptor(CaSR)	CaSR agonist	Mono	-
5	Hematology	Phase 3	AMG 531	Nplate	romiplostim	Thrombocytopenia, chemotherapy-induced	Protein	Thrombopoietin(TPO) receptor(CD110)	Thrombopoietin(TPO) receptor(CD110) agonist	Mono	-
6	Hematology	Phase 1	AMG176		tapotoclax	Hematologic disease	Small molecules	MCL1	MCL1 inhibitor	Mono	-
7	Immunology	Phase 3	CC-10004	Otezla	apremilast	Plaque psoriasis, pediatric	Small molecules	Phosphodiesterase-4(PDE-4)	PDE-4 inhibitor	Mono	-
8	Immunology	Phase 3	CC-10004	Otezla	apremilast	Psoriasis, genital	Small molecules	Phosphodiesterase-4(PDE-4)	PDE-4 inhibitor	Mono	-
9	Immunology	Phase 3	CC-10004	Otezla	apremilast	Psoriatic arthritis, juvenile	Small molecules	Phosphodiesterase-4(PDE-4)	PDE-4 inhibitor	Mono	-
10	Immunology	Phase 3	CC-10004	Otezla	apremilast	Palmoplantar pustulosis	Small molecules	Phosphodiesterase-4(PDE-4)	PDE-4 inhibitor	Mono	-
11	Immunology	Phase 3	AMG451		rocatinlimab	Atopic dermatitis	Antibody	TNFRSF4	TNFRSF4 antagonist	Mono	Kyowa Kirin

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	Mono/병용	파트너
12	Immunology	Phase 3		Tezspire	tezepelumab-ekko	Rhinosinusitis with nasal polyps, chronic	Antibody	TSLP	TSLP inhibitor	Mono	-
13	Immunology	Phase 2		Tezspire	tezepelumab-ekko	Obstructive pulmonary disease, chronic	Antibody	TSLP	TSLP inhibitor	Mono	-
14	Immunology	Phase 2		Tezspire	tezepelumab-ekko	Spontaneous urticaria, chronic	Antibody	TSLP	TSLP inhibitor	Mono	-
15	Immunology	Phase 2	AMG592		efavaleukin alfa	Systemic lupus erythematosus	Protein	N/A	N/A	Mono	-
16	Immunology	Phase 2	AMG592		efavaleukin alfa	Ulcerative colitis	Protein	N/A	N/A	Mono	-
17	Immunology	Phase 2	AMG714		ordesekimab	Celiac disease	Antibody	IL-15	IL-15 inhibitor	Mono	Genmab
18	Immunology	Phase 2	AMG570		rozibafusp alfa	Systemic lupus erythematosus	ADC	ICOS Ligand	ICOS Ligand inhibitor	Mono	-
19	Metabolic	Phase 1	AMG133			Obesity	ADC	GLP-1R	GLP-1R agonist	Mono	-
20	Metabolic	Phase 1	AMG609			Non-alcoholic steatohepatitis (NASH)	RNA	PNPLA3	ASO	Mono	-
21	Metabolic	Phase 1	AMG786			Obesity	Small molecules	N/A	N/A	Mono	-
22	Musculoskeletal	Phase 3	AMG 785	Evenity	romosozumab-aqqg	Osteoporosis, male	Antibody	Sclerostin(SOST)	SOST inhibitor	Mono	-
23	Musculoskeletal	Phase 3	AMG 162	Prolia	denosumab	Osteoporosis, pediatric, glucocorticoid-induced	Antibody	RANKL	RANKL inhibitor	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	Mono/병용	파트너
24	Musculoskeletal	Phase 3	AMG 162	Prolia	denosumab	Osteogenesis imperfecta, pediatric	Antibody	RANKL	RANKL inhibitor	Mono	-
25	Musculoskeletal	Phase 1	AMG 785	Evenity	romosozumab -aqqg	Osteogenesis imperfecta, pediatric	Antibody	Sclerostin(SOST)	SOST inhibitor	Mono	-
26	Neuroscience	Phase 3	AMG 334	Aimovig	erenumab -aooe	Migraine, pediatric	Antibody	CGRP	CGRP antagonist	Mono	-
27	Oncology	Phase 3	ZL-1303		bemarituzumab	Gastric and gastroesophageal junction cancers	Antibody	FGFR2b	Cytotoxic to cells expressing FGFR2b	Mono	-
28	Oncology	Phase 3	AMG 103	Blinicyto	blinatumomab	Acute lymphoblastic leukemia	Antibody	CD19, CD3	Bispecific antibody (CD19, CD3)	Mono	-
29	Oncology	Phase 3	PR-171	Kyprolis	carfilzomib	Multiple myeloma	Small molecules	Proteasome	Proteasome inhibitor	Mono	-
30	Oncology	Phase 3	AMG 510	Lumakras	sotorasib	Colorectal cancer, advanced	Small molecules	KRAS	KRAS inhibitor	Mono	-
31	Oncology	Phase 2	PR-171	Kyprolis	carfilzomib	Acute lymphoblastic leukemia, pediatric	Small molecules	Proteasome	Proteasome inhibitor	Mono	-
32	Oncology	Phase 2	AMG 510	Lumakras	sotorasib	NSCLC	Small molecules	KRAS	KRAS inhibitor	Mono	-
33	Oncology	Phase 2	AMG 510	Lumakras	sotorasib	Other tumors	Small molecules	KRAS	KRAS inhibitor	Mono	-
34	Oncology	Phase 2	AMG757		tarlatamab	Small cell lung cancer	Antibody	DLL3	Bispecific antibody (DLL3)	Mono	-
35	Oncology	Phase 1	ZL-1303		bemarituzumab	NSCLC	Antibody	FGFR2b	Cytotoxic to cells expressing FGFR2b	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	Mono/병용	파트너
36	Oncology	Phase 1	ZL-1303		bemarituzumab	Other tumors	Antibody	FGFR2b	Cytotoxic to cells expressing FGFR2b	Mono	-
37	Oncology	Phase 1	AMG757		tarlatamab	Prostate cancer, neuroendocrine	Antibody	DLL3	Bispecific antibody(DLL3)	Mono	-
38	Oncology	Phase 1	AMG160		acapatamab	Prostate cancer	Antibody	CD3, PSMA	Bispecific antibody(CD3, PSMA)	Mono	-
39	Oncology	Phase 1	AMG160		acapatamab	NSCLC	Antibody	CD3, PSMA	Bispecific antibody(CD3, PSMA)	Mono	-
40	Oncology	Phase 1	AMG119			Small cell lung cancer	Cell Therapy	DLL3	CAR-T	Mono	Gilead
41	Oncology	Phase 1	AMG193			Solid tumors	Small molecules	PRMT5	PRMT5 inhibitor	Mono	-
42	Oncology	Phase 1	AMG199			Solid tumors	Antibody	MUC17, CD3E	Cytotoxic to cells expressing MUC17, CD3E agonist	Mono	-
43	Oncology	Phase 1	AMG256			Solid tumors	Protein	IL-21	IL-21 antagonist	Mono	-
44	Oncology	Phase 1	AMG340			Prostate cancer	Antibody	CD3, Glutamate carboxypeptidase2	CD3 agonist, cytotoxic to cells expressing glutamate carboxypeptidase2	Mono	-
45	Oncology	Phase 1	AMG404		zeluvalimab	Solid tumors	Antibody	PD1	PD1 antagonist	Mono	-
46	Oncology	Phase 1	AMG427			Acute Myeloid Leukemia	Antibody	CD3, FLT3	CD3 agonist, cytotoxic to cells expressing FLT3	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	Mono/병용	파트너
47	Oncology	Phase 1	AMG509			Prostate cancer	Antibody	CD3, STEAP1	CD3 agonist, cytotoxic to cells expressing STEAP1	Mono	-
48	Oncology	Phase 1	AMG650			Solid tumors	Small molecules	KIF18A	KIF18A inhibitor	Mono	-
49	Oncology	Phase 1	AMG651			Colorectal cancer	Antibody	CD3, EGFR	CD3 agonist, cytotoxic to cells expressing EGFR	Mono	-
50	Respiratory	Phase 3		Tezspire	tezepelumab-ekko	Asthma	Antibody	TSLP	TSLP inhibitor	Mono	-
51	Respiratory	Phase 1	AMG104			Asthma	Antibody	TSLP	TSLP inhibitor	Mono	Astra Zeneca